Intellia Therapeutics, Inc.
In Vitro & In Vivo Diagnostic Substances · 40 ERIE STREET, SUITE 130, CAMBRIDGE, MA 02139
官方登记数据
0位关注者
2014成立于
关于 Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
Source: Wikipedia
行业In Vitro & In Vivo Diagnostic Substances
总部40 ERIE STREET, SUITE 130, CAMBRIDGE, MA 02139
成立2014
法律形式C Corporation
状态营业中
专利616 项专利
METHODS FOR IN VIVO EDITING OF KLKB1US20260240959A1 · 2026
IONIZABLE AMINE LIPIDSUS20260225997A1 · 2026
关键数据
法律信息
| 法定名称 | Intellia Therapeutics, Inc. |
|---|---|
| 法律形式 | C Corporation |
| SEC CIK | 1652130在 SEC EDGAR 上查看 ↗ |
| EIN | 36-4785571 |
| 行业代码(SIC) | 2835 |
| 注册地址 | 40 ERIE STREET, SUITE 130, CAMBRIDGE, MA 02139 |
| 状态 | 营业中 |
来源: SEC EDGAR · 更新于 Oct. 15, 2026
联系方式和链接
地点
40 ERIE STREET, SUITE 130, CAMBRIDGE, MA 02139
这是你的公司吗?
免费认领此页面,即可添加标志、产品、照片和职位,并回复评价。
认领此页面